Sanofi Mum on Genzyme as It Posts Higher Profit – New York Times (blog)
By Dr. Matthew Watson
 Reuters UK | Sanofi Mum on Genzyme as It Posts Higher Profit New York Times (blog) Sanofi-Aventis, the French pharmaceutical company considering an $18.6 billion bid for the American biotechnology firm Genzyme, said profits jumped in the ... Analysis: Past deals provide little help in valuing GenzymeReuters Report: Sanofi may make $18.7B bid for GenzymeBizjournals.com Biotechnology Stocks Posting Strong Gains In Late-Morning DealingRTT News BusinessWeek -StreetInsider.com (subscription) -ABC News all 520 news articles » |
Uncategorized
Comments Off on Sanofi Mum on Genzyme as It Posts Higher Profit – New York Times (blog) |
July 30th, 2010
This author published 5872 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research